Among these, KLC1-ALK represents a novel oncogenic fusion identified in lung cancer,28 while the KLC1-ROS1 fusion exerts oncogenic properties in glioma cells via specific activation of the JAK-STAT pathway.29 This evidence concerns the gene ROS1 and central nervous system cancer.